Among these, cerebrospinal fluid is the most commonly used method to assess AD progression, primarily by detecting Aβ42 or Aβ42:40 ratios, as well as total tau and phosphorylated tau levels [152]. The gene discussed is MAPT; the disease is Alzheimer disease.